GlassScriptPhysician profile
Lady C Dy
NPI 1467462929
$125,717.99
in general payments reported to CMS, 2019-2025
27 companies · $37K in 2025
The $37K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $173 · 2021: $88.67 · 2022: $252 · 2023: $47K · 2024: $41K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $90K · Travel and Lodging: $11K · Consulting Fee: $9,925 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,664 · Food and Beverage: $5,472 · Education: $74.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,232.50 |
| Travel and Lodging | $10,557.40 |
| Consulting Fee | $9,925.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,664.00 |
| Food and Beverage | $5,472.05 |
| Education | $74.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $66,834.32 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $31,464.48 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $23,988.88 | 2020-2025 | |
| Abbvie INC. | $1,457.50 | 2019-2025 | Botox |
| Galderma Laboratories, L.P. | $245.58 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $244.19 | 2024-2025 | Zoryve |
| Incyte Corporation | $224.49 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $169.19 | 2025 | Dupixent |
| Revance Therapeutics, INC. | $150.00 | 2024 | Daxxify |
| Almirall LLC | $141.29 | 2019-2025 | Klisyri |
| Mayne Pharma Commercial LLC | $107.29 | 2020-2025 | |
| Amgen INC. | $101.19 | 2019-2025 | Otezla |
| Vyne Pharmaceuticals INC. | $97.01 | 2020-2021 | |
| Genzyme Corporation | $95.69 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.59 | 2019-2024 | Cabtreo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $63.64 | 2025 | Venaseal |
| Dermavant Sciences, INC. | $35.74 | 2023-2024 | Vtama |
| Biofrontera INC. | $33.53 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organon LLC | $32.60 | 2025 | |
| Verrica Pharmaceuticals INC. | $29.36 | 2024 | Ycanth |
| Epi Health, LLC | $21.66 | 2021 | |
| Dermira, INC. | $21.43 | 2019 | |
| Mylan Pharmaceuticals INC. | $18.61 | 2019 | |
| Journey Medical Corporation | $15.41 | 2023 | |
| Mission Pharmacal Company | $14.59 | 2019 | |
| Botanix Sb INC | $14.40 | 2025 | Sofdra |
| Allergan, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lady Dy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.